Evidence map›Paper›PMID 40622110›Full record

Trial reportHead & neck2025

The DAHANCA 27 Phase II Study: Transoral Laser Microsurgery for T1aN0M0 Glottic Squamous Cell Carcinoma, a Comparison to Accelerated Radiotherapy.

Nina M Lyhne, Thomas Kjærgaard, Jesper F Tvedskov, Christian Godballe, Kirsten Hald, Benedicte P Ulhøi, Trine Printz, Jens Overgaard

Abstract readClinical Trial, Phase IIComparative Study
In one paragraph

Trial report in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nina M LyhneDepartment of Otorhinolaryngology - Head and Neck Surgery and Audiology, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0002-7675-1164
Thomas KjærgaardDepartment of Otorhinolaryngology - Head and Neck Surgery and Audiology, Aarhus University Hospital, Aarhus, Denmark.
Jesper F TvedskovDepartment of Otorhinolaryngology - Head and Neck Surgery and Audiology, Rigshospitalet, Copenhagen, Denmark.
Christian GodballeDepartment of Otorhinolaryngology - Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark and Clinical Department, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Kirsten HaldDepartment of Otorhinolaryngology - Head and Neck Surgery and Audiology, Aalborg University Hospital, Aalborg, Denmark.
Benedicte P UlhøiDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Trine PrintzDepartment of Otorhinolaryngology - Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark and Clinical Department, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
Jens OvergaardDepartment of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEndoscopic surgery of T1a glottic squamous cell carcinoma (SCC) is believed to have advantages compared to radiotherapy (RT), including short duration, cost-effectiveness, repeatability, and RT reserved for second tumors/failures. The equality of tumor control probability after treatments is unresolved.

methodsIn the DAHANCA 27 phase II study, selected Danish patients suspected of T1a glottic SCC between 2012 and 2016 were offered one-step diagnostic and curatively intended transoral laser microsurgery (TLM). The 5-year outcome was compared to a 2003-2012 national cohort of T1a glottic SCC patients treated with accelerated RT (accRT).

resultsThe TLM (n = 94) treatment included cordectomy type I (n = 44), II (n = 38), and III (n = 12). Failure was observed in 10/94 TLM and 36/534 accRT patients, resulting in 1 and 23 laryngectomies, respectively. The 5-year laryngectomy-free disease-specific survival was TLM 97.9% and accRT 94.6%, HR: 0.37 (0.09, 1.54).

conclusionsPrimary TLM for selected T1a glottic SCC patients is an organ preserving treatment with high disease control comparable to accRT.

Indexed as

Carcinoma, Squamous CellGlottisLaryngeal NeoplasmsLaser TherapyMicrosurgeryAdultAgedAged, 80 and overDenmarkDisease-Free SurvivalFemaleHumansLaryngectomyMaleMiddle AgedNatural Orifice Endoscopic Surgeryaccelerated radiotherapyearly glottic cancerlaser microsurgerynational cohortphase II study

Identifiers

PMID40622110
PMCPMC12617492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.